<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>4+7 &#8211; Accestra Consulting</title>
	<atom:link href="https://www.accestra.com/tag/47/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.accestra.com</link>
	<description>Your long term strategic partner for regulatory compliance.</description>
	<lastBuildDate>Mon, 03 Jun 2019 06:00:39 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.5.6</generator>

<image>
	<url>https://www.accestra.com/wp-content/uploads/2019/03/cropped-accestra2-32x32.png</url>
	<title>4+7 &#8211; Accestra Consulting</title>
	<link>https://www.accestra.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>The hottest generic drugs on China QCE battlefield</title>
		<link>https://www.accestra.com/the-hottest-generic-drugs-on-china-qce-battlefield/</link>
		
		<dc:creator><![CDATA[mona.zhang]]></dc:creator>
		<pubDate>Mon, 03 Jun 2019 05:56:38 +0000</pubDate>
				<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[4+7]]></category>
		<category><![CDATA[Quality Consistency Evaluation (QCE)，generic drug]]></category>
		<guid isPermaLink="false">http://www.accestra.com/?p=2381</guid>

					<description><![CDATA[Since the Quality Consistency Evaluation (QCE) reform has been implemented nationwide in 2016, there are two questions all pharmaceutical companies in China facing: whether to initiate a QCE project? If yes, what kind of generic drug should be selected? And since the medical insurance policies for generics such as 4+7 (11 pilot Chinese provinces) hospital&#8230;]]></description>
										<content:encoded><![CDATA[
<p>Since the Quality
Consistency Evaluation (QCE) reform has been implemented nationwide in 2016, there
are two questions all pharmaceutical companies in China facing: whether to
initiate a QCE project? If yes, what kind of generic drug should be selected? And
since the medical insurance policies for generics such as 4+7 (11 pilot Chinese
provinces) hospital centralized procurement is getting much clearer recently, it
seems the QCE is not only a race of company&#8217;s technical strength, financial
muscle and project management competence, but most important the perception
towards the entire Chinese pharmaceutical market. </p>



<p>Until the end of May 2019, the information published by CDE-NMPA shows that more than 1,100 QCE applications have been accepted after format review, involving over 340 pharmaceutical companies and more than 330 generic drugs. So which of them are the hottest ones?</p>



<div class="wp-block-image"><figure class="aligncenter"><img fetchpriority="high" decoding="async" width="1022" height="836" src="https://www.accestra.com/wp-content/uploads/2019/06/图片1.png" alt="" class="wp-image-2382" srcset="https://www.accestra.com/wp-content/uploads/2019/06/图片1.png 1022w, https://www.accestra.com/wp-content/uploads/2019/06/图片1-300x245.png 300w, https://www.accestra.com/wp-content/uploads/2019/06/图片1-768x628.png 768w, https://www.accestra.com/wp-content/uploads/2019/06/图片1-600x491.png 600w" sizes="(max-width: 1022px) 100vw, 1022px" /></figure></div>



<p>In addition, there
are already more than 20 generic specifications which over 3 pharmaceutical
company competitors have received regulatory approval of them under QCE system,
such as Amlodipine Besylate Tablets, Tenofovir disoproxil fumarate tablets, Rosuvastatin
Calcium Tablets and Metformin Hydrochloride Sustained-release Tablets, etc. However,
according to the new centralized procurement policy (4+7) which has enforced in
11 pilot Chinese provinces, if there are more than 3 pharmaceutical companies
providing the same drug approved under QCE system, the company whose drug has
not complete the consistency evaluation will be no more selected as the supplier.
Hence, for these hot generic drugs, the company without QCE approval has lost
the chance to stand on the boxing ring, and for those companies who got their QCE
tickets already, there is another round of price &amp; marketing fight
waiting for them.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
